

9.15-04

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Charles Allerson, et al. Confirmation No.: 5641

Application No.: 10/701,007 Group Art Unit: 1645

Filing Date: November 4, 2003 Examiner: Not Yet Assigned

For: COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED

NUCLEOSIDES FOR USE IN GENE MODULATIONS

EXPRESS MAIL LABEL NO: EL998519145US DATE OF DEPOSIT: September 14, 2004

→ EL998519145US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of request for				
	continued examination under § 1.114, no additional fee is required.				
	In accordance with § 1.97(c), this Information Disclosure Statement is being				
	filed after the period set forth in § 1.97(b) above but before the mailing date of				
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or				
	before an action that otherwise closes prosecution in the application, therefore:				
	Certification in Accordance with § 1.97(e) is attached; or				
	The fee of \$180.00 as set forth in § 1.17(p) is attached.				
	In accordance with § 1.97(d), this Information Disclosure Statement is being				
	filed after the mailing date of either a Final Action under § 1.113 or a Notice				
	of Allowance under § 1.311 but before, or simultaneously with, the payment				
	of the Issue Fee, therefore included are: Certification in Accordance with §				
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).				
\boxtimes	Copies of reference numbers 104 - 111 listed on the attached Form PTO-1449				
	are enclosed herewith.				
	A copy of reference number 112 on the attached Form PTO 1449 is not				
	required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).				
	Copies of references - are not being submitted because				
	they were previously cited by or submitted to the U.S. Patent and				
	Trademark Office in patent application number , filed for				
	which a claim for priority under 35 U.S.C. § 120 has been made in the				
	instant application.				
The r	relevance of those listed references which are not in the English language is as ws:				

Enclosed is a copy of the PCT International Search Report dated August 23, 2004 (number 104 on Form PTO-1449), which indicates the references considered to be relevant.

- 3 -

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date:

September 14, 2004

John A. Harrelson, Jr. Registration No. 42,637

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2004 WW





Form PTO	-1449 Modified	Docket No. ISIS-5325	Application No. 10/701,007				
Cited b	t and Publications by Applicant sheets if necessary)	Applicant Charles Allerson, et al.					
	nent of Commerce Trademark Office	Filing Date November 4, 2003	Group 1645				
	•	Confirmation No. 5641					
OTHE	R DOCUMENTS (Incl	uding Author, Title, Da	te, Pertinent Pages, Etc.)				
104	Copy of the PCT International Search Report dated August 23, 2004 (PCT/US03/35063)						
105							
106							
107		, "Structural variations and stabilizing modifications of synthetic ian cells," <i>Nucleic Acids Res.</i> , 2003 , <i>31(11)</i> , 2705-2716					
108	Elbashir S.M., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , 2001 , <i>411</i> , 494-498						
109							
110	Sui, G., et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , 2002 , <i>99(8)</i> , 5515-5520						
111	Yu, JY., et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , 2002 , <i>99(9)</i> , 6047-6052						
EXAMINER		DATE CO	DATE CONSIDERED				

Form PTO-1449 Modified				Docket No. ISIS-5325	Application No. 10/701,007			
	Cite	tent and Publications d by Applicant al sheets if necessary		Applicant Charles Allerson, et al.				
		artment of Commerce ad Trademark Office	e	Filing Date November 4, 2003	Group 1645			
:				Confirmation No. 5641				
		U. :	S. PATENT	T DOCUMENTS	<u> </u>			
Examiner Initial		Document No.	Date	Name		Class	Subclass	
	112	2003/0143732 A1	07/31/03	Fosnaugh, et al.		435	325	
		FORE	IGN PATE	ENT DOCUMENTS				
Examiner						Tra	nslation	
Initial		Document No.	Date	Country		YES	NO	
								
EXAMINER				DATE CONSIDER)FD			